CHR 5154
Alternative Names: 3117391; CHR-5154; CHR-5426; GSK 3117391Latest Information Update: 02 Jul 2023
At a glance
- Originator Chroma Therapeutics
- Developer Chroma Therapeutics; GSK
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-I for Rheumatoid arthritis (In volunteers) in United Kingdom (PO)
- 28 Sep 2021 Discontinued - Phase-II for Rheumatoid arthritis in Poland (PO)
- 28 Sep 2021 Discontinued - Phase-II for Rheumatoid arthritis in Romania (PO)